Optimization of Substituted 6-Salicyl-4-Anilinoquinazoline Derivatives as Dual EGFR/HER2 Tyrosine Kinase Inhibitors

• Dong-Dong Li ,

  Contributed equally to this work with: Dong-Dong Li, Ya-Juan Qin

  Affiliation State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, P. R. China

  ⨯
• Ya-Juan Qin ,

  Contributed equally to this work with: Dong-Dong Li, Ya-Juan Qin

  Affiliation State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, P. R. China

  ⨯
• Jian Sun,

  Affiliation State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, P. R. China

  ⨯
• Jing-Ran Li,

  Affiliation State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, P. R. China

  ⨯
• Fei Fang,

  Affiliation State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, P. R. China

  ⨯
• Qian-Ru Du,

  Affiliation State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, P. R. China

  ⨯
• Yong Qian,

  Affiliation State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, P. R. China

  ⨯
• Hai-Bin Gong ,

  * E-mail: zhuhl@nju.edu.cn (HLZ); ghbxzh@yahoo.com.cn (HBG)

  Affiliation Xuzhou Central Hospital, Xuzhou, P. R. China

  ⨯
• Hai-Liang Zhu

  * E-mail: zhuhl@nju.edu.cn (HLZ); ghbxzh@yahoo.com.cn (HBG)

  Affiliation State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, P. R. China

  ⨯